Hepion director gets 299K stock options at $0.08
Hepion Pharmaceuticals, Inc. (HEPA) reported that director Michael J. Purcell received a grant of stock options on August 19, 2026 to acquire 299,000 shares of common stock at an exercise price of $0.08 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. (HEPA) reported that director Michael J. Purcell received a grant of stock options on August 19, 2026 to acquire 299,000 shares of common stock at an exercise price of $0.08 per share. These options become exercisable on August 19, 2027 and expire on August 19, 2036, leaving him with 299,000 options held directly after the award. No Rule 10b5-1 trading plan is reported for this grant.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 299,000 | $0.00 | $0.00 |
Key Figures
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did HEPA disclose for Michael J. Purcell?
What is the exercise price of Michael J. Purcell’s HEPA stock options?
When do the newly granted HEPA stock options become exercisable and when do they expire?
Were Michael J. Purcell’s HEPA option grants made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.